{"id":49131,"date":"2025-11-28T16:05:46","date_gmt":"2025-11-28T08:05:46","guid":{"rendered":"https:\/\/flcube.com\/?p=49131"},"modified":"2025-11-28T16:05:47","modified_gmt":"2025-11-28T08:05:47","slug":"trulive-medical-closes-series-c-raising-over-rmb-100m-for-cardiovascular-innovation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=49131","title":{"rendered":"Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation"},"content":{"rendered":"\n<p><strong>Jiangsu Trulive Medical<\/strong> announced the completion of a <strong>Series C financing round<\/strong> raising <strong>over RMB 100\u202fmillion<\/strong>, co\u2011led by <strong>Oriental Fortune Capital<\/strong> and <strong>Guoyuan Equity<\/strong>, with participation from <strong>Xiamen Industry Investment<\/strong>, <strong>Xiamen Gold Innovation<\/strong>, <strong>Bo Zheng Capital<\/strong>, <strong>Siming Science &amp; Technology Innovation<\/strong>, and existing shareholder <strong>Lifetree Capital<\/strong>. Proceeds will expand the company&#8217;s <strong>national base network<\/strong> for structural heart disease devices, focusing on <strong>mitral and tricuspid valve therapies<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financing-details\">Financing Details<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Jiangsu Trulive Medical<\/td><\/tr><tr><td><strong>Round<\/strong><\/td><td>Series C<\/td><\/tr><tr><td><strong>Amount<\/strong><\/td><td>Over RMB 100\u202fmillion<\/td><\/tr><tr><td><strong>Lead Investors<\/strong><\/td><td>Oriental Fortune Capital, Guoyuan Equity<\/td><\/tr><tr><td><strong>Co\u2011Investors<\/strong><\/td><td>Xiamen Industry Investment\/Venture Capital, Xiamen Gold Innovation, Bo Zheng Capital, Siming Science &amp; Technology Innovation<\/td><\/tr><tr><td><strong>Existing Shareholder<\/strong><\/td><td>Lifetree Capital<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2019<\/td><\/tr><tr><td><strong>Use of Proceeds<\/strong><\/td><td>Deploy national base network, R&amp;D core, manufacturing cluster, production bases<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-company-profile\">Company Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Focus:<\/strong> Cardiovascular diseases, specifically <strong>structural heart disease<\/strong> sector<\/li>\n\n\n\n<li><strong>Flagship Products:<\/strong> <strong>Mitral and tricuspid valve<\/strong> therapies<\/li>\n\n\n\n<li><strong>Market Need:<\/strong> Cardiovascular diseases have <strong>extremely high mortality and disability rates<\/strong> with <strong>limited domestic solutions<\/strong><\/li>\n\n\n\n<li><strong>Competitive Moat:<\/strong> <strong>Differentiated advantage<\/strong> in mitral\/tricuspid valve tracks vs. competitors focused on aortic valves<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-deployment-plan\">Strategic Deployment Plan<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Function<\/th><th>Timeline<\/th><\/tr><\/thead><tbody><tr><td><strong>Shanghai<\/strong><\/td><td>R&amp;D core<\/td><td>Established<\/td><\/tr><tr><td><strong>Yangtze River Delta<\/strong><\/td><td>High\u2011end manufacturing cluster<\/td><td>2026\u20112027<\/td><\/tr><tr><td><strong>Key Regions<\/strong><\/td><td>R&amp;D and production bases<\/td><td>2027\u20112028<\/td><\/tr><tr><td><strong>Objective<\/strong><\/td><td>National coverage via multi\u2011base synergy<\/td><td>Full deployment by 2028<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Value<\/th><\/tr><\/thead><tbody><tr><td><strong>China Structural Heart Disease Market<\/strong><\/td><td>\u00a515\u202fbillion (2024)<\/td><\/tr><tr><td><strong>Mitral\/Tricuspid Valve Segment<\/strong><\/td><td>\u00a53.5\u202fbillion; growing 25% CAGR<\/td><\/tr><tr><td><strong>Addressable Patient Pool<\/strong><\/td><td>~500,000 patients eligible for mitral\/tricuspid intervention<\/td><\/tr><tr><td><strong>Revenue Forecast<\/strong><\/td><td><strong>\u00a5800\u202fmillion\u20111.2\u202fbillion<\/strong> by 2030<\/td><\/tr><tr><td><strong>Market Share Target<\/strong><\/td><td>15\u201120% of mitral\/tricuspid segment<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing:<\/strong> Multi\u2011base strategy enables <strong>local production<\/strong>, reducing costs and improving supply chain resilience<\/li>\n\n\n\n<li><strong>Regulatory Path:<\/strong> Class\u202fIII medical device pathway; key products in <strong>late\u2011stage clinical trials<\/strong><\/li>\n\n\n\n<li><strong>Next Catalyst:<\/strong> First mitral valve product launch expected <strong>H2\u202f2026<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Trulive Medical\u2019s financing utilization, product launch timelines, and market penetration. Actual results may differ materially due to risks including regulatory approvals, competitive responses, and execution of multi\u2011base strategy.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Trulive Medical announced the completion of a Series C financing round raising over RMB&#8230;<\/p>\n","protected":false},"author":1,"featured_media":49290,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[4480],"class_list":["post-49131","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-trulive-medical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Trulive Medical announced the completion of a Series C financing round raising over RMB 100\u202fmillion, co\u2011led by Oriental Fortune Capital and Guoyuan Equity, with participation from Xiamen Industry Investment, Xiamen Gold Innovation, Bo Zheng Capital, Siming Science &amp; Technology Innovation, and existing shareholder Lifetree Capital. Proceeds will expand the company&#039;s national base network for structural heart disease devices, focusing on mitral and tricuspid valve therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=49131\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation\" \/>\n<meta property=\"og:description\" content=\"Jiangsu Trulive Medical announced the completion of a Series C financing round raising over RMB 100\u202fmillion, co\u2011led by Oriental Fortune Capital and Guoyuan Equity, with participation from Xiamen Industry Investment, Xiamen Gold Innovation, Bo Zheng Capital, Siming Science &amp; Technology Innovation, and existing shareholder Lifetree Capital. Proceeds will expand the company&#039;s national base network for structural heart disease devices, focusing on mitral and tricuspid valve therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=49131\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-28T08:05:46+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-28T08:05:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2801.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49131#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49131\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation\",\"datePublished\":\"2025-11-28T08:05:46+00:00\",\"dateModified\":\"2025-11-28T08:05:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49131\"},\"wordCount\":345,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49131#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2801.webp\",\"keywords\":[\"Trulive Medical\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49131#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49131\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=49131\",\"name\":\"Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49131#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49131#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2801.webp\",\"datePublished\":\"2025-11-28T08:05:46+00:00\",\"dateModified\":\"2025-11-28T08:05:47+00:00\",\"description\":\"Jiangsu Trulive Medical announced the completion of a Series C financing round raising over RMB 100\u202fmillion, co\u2011led by Oriental Fortune Capital and Guoyuan Equity, with participation from Xiamen Industry Investment, Xiamen Gold Innovation, Bo Zheng Capital, Siming Science & Technology Innovation, and existing shareholder Lifetree Capital. Proceeds will expand the company's national base network for structural heart disease devices, focusing on mitral and tricuspid valve therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49131#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=49131\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49131#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2801.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/11\\\/2801.webp\",\"width\":1080,\"height\":608,\"caption\":\"Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=49131#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Trulive Medical announced the completion of a Series C financing round raising over RMB 100\u202fmillion, co\u2011led by Oriental Fortune Capital and Guoyuan Equity, with participation from Xiamen Industry Investment, Xiamen Gold Innovation, Bo Zheng Capital, Siming Science & Technology Innovation, and existing shareholder Lifetree Capital. Proceeds will expand the company's national base network for structural heart disease devices, focusing on mitral and tricuspid valve therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=49131","og_locale":"en_US","og_type":"article","og_title":"Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation","og_description":"Jiangsu Trulive Medical announced the completion of a Series C financing round raising over RMB 100\u202fmillion, co\u2011led by Oriental Fortune Capital and Guoyuan Equity, with participation from Xiamen Industry Investment, Xiamen Gold Innovation, Bo Zheng Capital, Siming Science & Technology Innovation, and existing shareholder Lifetree Capital. Proceeds will expand the company's national base network for structural heart disease devices, focusing on mitral and tricuspid valve therapies.","og_url":"https:\/\/flcube.com\/?p=49131","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-11-28T08:05:46+00:00","article_modified_time":"2025-11-28T08:05:47+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2801.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=49131#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=49131"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation","datePublished":"2025-11-28T08:05:46+00:00","dateModified":"2025-11-28T08:05:47+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=49131"},"wordCount":345,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=49131#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2801.webp","keywords":["Trulive Medical"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=49131#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=49131","url":"https:\/\/flcube.com\/?p=49131","name":"Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=49131#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=49131#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2801.webp","datePublished":"2025-11-28T08:05:46+00:00","dateModified":"2025-11-28T08:05:47+00:00","description":"Jiangsu Trulive Medical announced the completion of a Series C financing round raising over RMB 100\u202fmillion, co\u2011led by Oriental Fortune Capital and Guoyuan Equity, with participation from Xiamen Industry Investment, Xiamen Gold Innovation, Bo Zheng Capital, Siming Science & Technology Innovation, and existing shareholder Lifetree Capital. Proceeds will expand the company's national base network for structural heart disease devices, focusing on mitral and tricuspid valve therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=49131#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=49131"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=49131#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2801.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2801.webp","width":1080,"height":608,"caption":"Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=49131#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Trulive Medical Closes Series C, Raising Over RMB 100M for Cardiovascular Innovation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/11\/2801.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=49131"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49131\/revisions"}],"predecessor-version":[{"id":49289,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/49131\/revisions\/49289"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/49290"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=49131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=49131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=49131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}